APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study.

Young BA, Wilson JG, Reiner A, Kestenbaum B, Franceschini N, Bansal N, Correa A, Himmelfarb J, Katz R. APOL1, Sickle Cell Trait, and CKD in the Jackson Heart Study. Kidney medicine. 2021 Jul 15; 3(6):962-973.e1, DOI: 10.1016/j.xkme.2021.05.004.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

RATIONALE and OBJECTIVE: Apolipoprotein L1 ( < i > APOL1 < /i > ) high-risk variants are associated with an increased risk for chronic kidney disease (CKD) among African Americans. Less is known regarding the risk for the development of CKD and kidney failure (end-stage kidney disease [ESKD]) among African Americans with only 1 < i > APOL1 < /i > risk variant or whether the risk is modified by sickle cell trait. STUDY DESIGN: The Jackson Heart Study is a community-based longitudinal cohort study. SETTING and PARTICIPANTS: Self-reported African Americans in the Jackson Heart Study (n  = 5,306). EXPOSURES: < i > APOL1 < /i > G1 and G2 genotypes and sickle cell trait. OUTCOMES: Incident CKD (estimated glomerular filtration rate  < 60 mL/min/1.73 m), albuminuria (urinary albumin-creatinine ratio  = 30 mg/g), continuous and rapid kidney function decline ( = 30% decline), and incident ESKD. ANALYTICAL APPROACH: Multivariable linear and logistic regression, and Cox proportional hazards models adjusted for age, sex, hypertension, diabetes, ancestry informative markers, and sickle cell trait. RESULTS: Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 < i > APOL1 < /i > risk variants. Sickle cell trait was present in 8.5%. Compared with participants with zero < i > APOL1 < /i > risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57), continuous decline (ß  =  -1.90; 95% CI, -3.35 to -0.45), and rapid kidney function decline (OR, 2.21; 95% CI, 1.22 to 4.00) after adjustment for sickle cell trait, with similar results after adjustment for ancestry informative markers. Having 1 < i > APOL1 < /i > risk variant was not associated with CKD outcomes and there was no interaction of < i > APOL1 < /i > with sickle cell trait. LIMITATIONS: Single-site recruitment of African American individuals with < i > APOL1 < /i > and sickle cell trait. CONCLUSIONS: The presence of 1 < i > APOL1 < /i > risk allele was not associated with increased risk for CKD outcomes, whereas 2 risk alleles were associated with incident albuminuria, CKD, ESKD, and rapid and continuous kidney function decline. Additional studies are needed to determine factors that might alter the risk for adverse kidney outcomes among individuals with high-risk < i > APOL1 < /i > genotypes.